Sanders Morris Harris LLC Purchases Shares of 24,975 Bausch Health Companies Inc. (NYSE:BHC)

Sanders Morris Harris LLC purchased a new stake in Bausch Health Companies Inc. (NYSE:BHC) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 24,975 shares of the company’s stock, valued at approximately $195,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Steward Financial Group LLC bought a new position in shares of Bausch Health Companies in the 4th quarter valued at about $40,000. Acrisure Capital Management LLC bought a new position in shares of Bausch Health Companies in the 4th quarter valued at about $70,000. Oakworth Capital Inc. grew its position in shares of Bausch Health Companies by 22.9% in the 1st quarter. Oakworth Capital Inc. now owns 9,952 shares of the company’s stock valued at $81,000 after acquiring an additional 1,852 shares during the period. FMR LLC grew its position in shares of Bausch Health Companies by 58.3% in the 2nd quarter. FMR LLC now owns 10,057 shares of the company’s stock valued at $84,000 after acquiring an additional 3,703 shares during the period. Finally, NewEdge Advisors LLC bought a new position in shares of Bausch Health Companies in the 2nd quarter valued at about $95,000. 74.56% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Bausch Health Companies news, EVP Seana Carson sold 6,685 shares of Bausch Health Companies stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $8.28, for a total value of $55,351.80. Following the completion of the sale, the executive vice president now owns 385,213 shares in the company, valued at approximately $3,189,563.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 13.75% of the company’s stock.

Bausch Health Companies Price Performance

Shares of Bausch Health Companies stock opened at $8.52 on Friday. Bausch Health Companies Inc. has a twelve month low of $5.57 and a twelve month high of $10.23. The company has a quick ratio of 0.81, a current ratio of 1.12 and a debt-to-equity ratio of 74.20. The company has a 50-day simple moving average of $8.76 and a two-hundred day simple moving average of $7.99. The stock has a market capitalization of $3.08 billion, a price-to-earnings ratio of -16.71 and a beta of 0.98.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.06. Bausch Health Companies had a negative net margin of 2.23% and a positive return on equity of 411.18%. The business had revenue of $2.17 billion during the quarter, compared to analysts’ expectations of $2.04 billion. Analysts forecast that Bausch Health Companies Inc. will post 3.29 EPS for the current year.

Wall Street Analyst Weigh In

BHC has been the subject of a number of analyst reports. StockNews.com initiated coverage on shares of Bausch Health Companies in a research report on Thursday, August 17th. They issued a “hold” rating for the company. TD Cowen downgraded shares of Bausch Health Companies from an “outperform” rating to a “market perform” rating in a report on Friday, June 16th. Jefferies Financial Group lifted their target price on shares of Bausch Health Companies from $7.00 to $9.50 in a report on Monday, May 22nd. Finally, Royal Bank of Canada lifted their target price on shares of Bausch Health Companies from $8.00 to $9.00 and gave the stock a “sector perform” rating in a report on Monday, July 24th.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.